ARTICLE | Clinical News

VEC-162: Additional Phase II data

July 3, 2006 7:00 AM UTC

In a double-blind Phase II trial in 37 healthy volunteers, 50 mg and 100 mg of VEC-162 led to a significant shift in circadian rhythm of up to 5 hours in the first night vs. placebo (p<0.025). Also, 1...